The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Impact of dabigatran on a large panel of routine or specific coagulation assays: Laboratory recommendations for monitoring of dabigatran etexilate
Abstract
Summary: Due to low bioavailability and high inter-individual variability, monitoring of dabigatran may be required in specific situations to prevent the risk of bleedings or thrombosis. The aim of the study was to determine which coagulation assay(s) could be used to assess the impact of dabig-atran on secondary haemostasis. Dabigatran was spiked at concentrations ranging from 4.7 ng/ml to 943.0 ng/ml in pooled citrated human platelet-poor plasma. The following clotting assays were performed: prothrombin time (PT); activated partial thromboplastin time (aPTT); thrombin time (TT); ecarin clotting time (ECT); ecarin chromo-genic assay (ECA); prothrombinase-induced clotting time (PiCT); activated clotting time (ACT); Hemoclot Thrombin Inhibitor (HTI) and thrombin generation assay (TGA). A concentration-dependent prolongation of PT, dPT, and aPTT was observed with aPTT being the more sensitive test. The results varied mostly due to the clotting reagent. HTI, ECT and TGA were the most sensitive tests but are not available 24 hours a day. In addition, HTI showed a linear correlation with a good reproduci-bility. Dabigatran induced a concentration-dependent delay and inhibition of tissue factor-induced TGA. Cut-offs related with higher risk of bleedings or thrombosis were defined for each reagent of aPTT and HTI. In conclusion, aPTT could be used for the monitoring of dabigatran and as screening test for the risk of overdose. However, because of its higher sensitivity, good reproducibility, excellent linear correlation at all doses, its simplicity of use, and possibilities of automation, HTI should be considered as the gold-standard.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Calibrated Automated Thrombin Generation Measurement in Clotting Plasma
Hemker, H. C., Giesen, P., Al Dieri, R., Regnault, V., de Smedt, E., Wagenvoord, R., Lecompte, T., & Béguin, S. (2003) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000071636 · Cited by 1,430
Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Newly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Stangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
Martinoli, J.-L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., Perzborn, E., & Samama, M. M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0176 · Cited by 449
Conflicts of interest: none declared
Suga, H., Eto, H., Inoue, K., Aoi, N., Kato, H., Araki, J., Higashino, T., Yoshimura, K., Yoshimura, K., Publication, A. F., et al. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0007 · Cited by 442
Stangier, J., Stähle, H., Rathgen, K., & Fuhr, R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00005 · Cited by 427
Ezekowitz, M. D., Reilly, P. A., Nehmiz, G., Simmers, T. A., Nagarakanti, R., Parcham-Azad, K., Pedersen, K. E., Lionetti, D. A., Stangier, J., & Wallentin, L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.034 · Cited by 419
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
Baghaei, F., Blixter, I. F., Gustafsson, K., Stigendal, L., Sten-Linder, M., Strandberg, K., Hillarp, A., Lindahl, T., & and from the expert group on coagulation of the External Quality Assurance in Laboratory Medicine in Sweden (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-06-0342 · Cited by 269
Stassen, J.-M., Priepke, H., Ries, U. J., Hauel, N., & Wienen, W. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-03-0183 · Cited by 250
Godier, A., Miclot, A., Le Bonniec, B., Durand, M., Fischer, A.-M., Emmerich, J., Marchand-Leroux, C., Lecompte, T., & Samama, C.-M. (2012) · Anesthesiology · doi:10.1097/aln.0b013e318238c036 · Cited by 246
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
Nutescu, E., Chuatrisorn, I., & Hellenbart, E. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0561-1 · Cited by 243
New oral anticoagulant drugs in cardiovascular disease
Lip, G., Peter, K., & Ahrens, I. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-05-0327 · Cited by 227
Laboratory assessment of new anticoagulants
Samama, M. M., & Guinet, C. (2011) · cclm · doi:10.1515/cclm.2011.134 · Cited by 174
Monitoring unfractionated heparin with the aPTT: Time for a fresh look
Hirsh, J., & Eikelboom, J. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-05-0290 · Cited by 174
Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents
LEVI, M., EERENBERG, E., & KAMPHUISEN, P. W. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04432.x · Cited by 170
Crippa, L., Falanga, A., Finazzi, G., Marongiu, F., Palareti, G., Poli, D., Testa, S., Tiraferri, E., Tosetto, A., Tripodi, A., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-05-0358 · Cited by 159
Freyburger, G., Macouillard, G., Labrouche, S., & Sztark, F. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.01.001 · Cited by 157
To bleed or not to bleed? is that the question for the PTT?
Kitchens, C. S. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01552.x · Cited by 151
Ufer, M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-09-0659 · Cited by 129
Baetz, B., & Spinler, S. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.11.1354 · Cited by 107
New oral antithrombotics: a need for laboratory monitoring. For
Mismetti, P., & Laporte, S. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03764.x · Cited by 91
Shortened activated partial thromboplastin time: causes and management
Lippi, G., Salvagno, G. L., Ippolito, L., Franchini, M., & Favaloro, E. J. (2010) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328338dbe8 · Cited by 69
Cited by
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Metadata
- Authors
- Robert, S., Chatelain, C., Douxfils, J., Mullier, F., Chatelain, B., & Dogné, J.-M.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2012
- Volume
- 107
- Issue
- 05
- Pages
- 985-997
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2156970332
- Cited by
- 325
- References
- 28
- FWCI
- 34.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.